Computational chemistry

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Biochemistry #Biomarkers #Business #Cell therapy #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #Immunology #Lead discovery #Metabolomics #Molecular medicine #Oncology #Pharmacology #Precision medicine #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry

Early Patient Stratification is Critical to Enable Effective and Personalised Drug Discovery and Development

Early Patient Stratification is Critical to Enable Effective and Personalised Drug Discovery and Development By Dr David A Fryburg, Dr Diane H Song and Dr David de Graaf With the current chances of an efficacious outcome in Phase II for novel mechanisms being in the region of 1 in 5,… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Business #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Enabling technologies #High Content Screening #High throughput screening #Immunology #Lead discovery #Lead optimisation #Mass spectrometry / NMR #Medicinal chemistry #Microfluidics #Organic chemistry #RNA #Screening #System biology #Systems biology #Therapeutics #Toxicology

Next Generation Flow Chemistry and Biology Platforms: The Impact on Small Molecule Drug Discovery

Next Generation Flow Chemistry and Biology Platforms: The Impact on Small Molecule Drug Discovery By Dr J Mark Treherne, Dr David M Parry and Christopher N Selway Can the next generation of flow chemistry and biology platforms be fully integrated to transform the efficiency of small-molecule drug discovery for pharmaceutical… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Automation / robotics #Biochemistry #Business #Chemical engineering #Chemistry #Clinical specialities #Computational chemistry #Drug development #Drug discovery #Genomics #Lead discovery #Medicinal chemistry #Microfluidics #RNA

Assessing the Value of R&D Partnerships

Assessing the Value of R&D Partnerships By Dr David A Pardoe, Dr Jackie Hunter MBE, Dr Robert M Cooke and Dr Paul Barrett In response to the need to increase the return on investment in R&D, many large Pharma companies are shifting from an internal fixed resource model to more… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Cell therapy #Chemical engineering #Chemistry #Computational chemistry #Drug development #Drug discovery #Gene therapy #High Content Screening #Isotope labelling #Lead discovery #Organic chemistry #Pharmacology #RNA #Stem cells

Neutron Scattering Provides Unique Insights for Drug R&D

Neutron Scattering Provides Unique Insights for Drug R&D By Dr Martyn Bull Drug discovery and development is a long and expensive process. Techniques, such as computer modelling, that make the search for promising candidates easier are usually taken up enthusiastically. Neutron scattering, an emerging technique in this field, can provide… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Business #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical trials #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Drug targets #High Content Screening #High throughput screening #Imaging #Lead discovery #Lead optimisation #Microfluidics #Pharmacology #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Toxicology

Overcoming Bottlenecks in Drug Discovery

Overcoming Bottlenecks in Drug Discovery By Dr Trevor Perrior Developing a new drug is an expensive and time-consuming process. The best current estimate puts the cost of developing a single new drug at close to $1 billion. After a drug candidate has entered the clinical trial process it takes, on… Read More

#Archive

Electronic laboratory notebook (ELN)
#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Automation / robotics #Biologics / Biotechnology #Business #Chemical engineering #Chemistry #Computational chemistry #Drug development #High Content Screening #Mass spectrometry / NMR #Pharmacology #Pharmokinetics #Preclinical #Regulatory #RNA #Sequencing #System biology #Systems biology #Target validation

Enterprise ELNs as a Foundation for Preclinical Drug Development

Enterprise ELNs as a Foundation for Preclinical Drug Development By Simon Beaulah, Dr Paul Denny- Gouldson and Dr Scott Weiss To have real business impact within preclinical drug development, Enterprise ELNs (Electronic Laboratory Notebooks) must provide a secure, scalable and searchable data management backbone across all disciplines focused on development… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cellular assays #Chemical engineering #Chemistry #Clinical trials #Computational chemistry #Drug development #Drug discovery #Genetics / genomes #Genetics / genomics #High Content Screening #High throughput screening #Lead discovery #Mass spectrometry / NMR #Metabolomics #Molecular medicine #PCR #Protein chemistry / Proteomics #RNA #Screening #Sequencing #Target validation #Toxicology #Translational #Translational chemistry

Towards Unbiased Biomarker Discovery

Towards Unbiased Biomarker Discovery Dr Jens Hoefkens High-throughput molecular profiling technologies are routinely applied for biomarker discovery to make the drug discovery process more efficient and enable personalised medicine. The ability to find novel biomarkers rests on large-scale data generation and unbiased data analysis. Over the past decade, biomarker discovery… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Biochemistry #Business #Cellular & Molecular biology #Cellular assays #Clinical specialities #Computational chemistry #Drug discovery #Drug targets #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #PCR #Screening #Toxicology

Compound Profiling: Size impact on primary screening libraries

By William Downey, Cindy Liu and Dr Jennifer Hartigan A recent report examines the trends in utilisation of compound libraries, as well as the impact of profiling on the size of screening decks. The drivers for choosing between large or focused libraries may be different, but the ultimate goal remains… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development optimisation & technology #Biomarkers #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Computational chemistry #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Lead discovery #Medicinal chemistry #Molecular medicine #Oncology #Pharmacology #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Toxicology #Translational #Translational chemistry

Utilising 3D nuclear DNA methylation patterns in cell-based assays for epigenetic drug screening

Utilising 3D nuclear DNA methylation patterns in cell-based assays for epigenetic drug screening By Professor Jian Tajbakhsh, Professor Arkadiusz Gertych and Professor Daniel L Farkas Since epigenetic changes are thought to underlie a wide range of complex diseases, the scope of epigenetic drug therapy is likely to expand, as epigenetic… Read More

#Archive

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Animal models #Assay development optimisation & technology #Biochemistry #Business #Chemical engineering #Chemistry #Clinical specialities #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Imaging #In Silico Biology #Lead discovery #Lead optimisation #Medicinal chemistry #Molecular medicine #Organic chemistry #Orphan drugs #Preclinical #Regulatory #RNA #Screening #System biology #Systems biology #Target validation #Toxicology

Free Online Resources Enabling Crowd-Sourced Drug Discovery

Free Online Resources Enabling Crowd-Sourced Drug Discovery By Dr Antony J. Williams, Valery Tkachenko, Dr Chris Lipinski, Professor Alexander Tropsha and Dr Sean Ekins The availability of freely accessible online resources to enable and support drug discovery has blossomed in recent years. The PubChem platform is now accompanied by a… Read More

#Archive

#AI / data analytics / healthtech / informatics #Biochemistry #Cellular & Molecular biology #Cellular assays #Chemistry #Computational chemistry #Drug development #Drug discovery #Drug targets #High Content Screening #Lead discovery #Lead optimisation #Medicinal chemistry #Protein chemistry / Proteomics #RNA #Screening #Stem cells #Toxicology #Translational #Translational chemistry

Integrating Computational Methods and Drug Discovery – Avoiding pitfalls in chemical space

Integrating Computational Methods and Drug Discovery - Avoiding pitfalls in chemical space By Alexandre Ismail and Professor Philippe Manivet The immensity of the task in discovering suitable molecules for development among the vast number which are theoretically available is well stated. With 90% of potentially efficacious compounds failing at latter… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Automation / robotics #Biochemistry #Cellular & Molecular biology #Chemical engineering #Chemistry #Computational chemistry #Drug development #Drug discovery #Drug targets #High Content Screening #High throughput screening #Immunology #Lead discovery #Lead optimisation #PCR #Pharmacology #RNA #Screening #System biology #Systems biology #Therapeutics

Structure-Based Drug Design – Will crystallisation ‘chaperones’ make all proteins crystallisable?

Structure-Based Drug Design - Will crystallisation 'chaperones' make all proteins crystallisable? By Dr Chun-wa Chung Macromolecular x-ray crystallography is usually an integral part of small molecule drug discovery for soluble targets. Recent advances in the crystallography of membrane proteins, such as ion channels and G-protein-coupled receptors, have opened up the… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Automation / robotics #Business #Cell culture #Chemical engineering #Chemistry #Clinical trials #Computational chemistry #Drug development #Drug discovery #Genomics #Immunology #Lead discovery #Microbiology #Molecular medicine #Oncology #Organic chemistry #Preclinical #Regulatory #RNA #Therapeutics

A perspective on scientific innovation in the pharmaceutical industry

Share Share Tweet Email A perspective on scientific innovation in the pharmaceutical industry A perspective on scientific innovation in the pharmaceutical industry By Dr Joseph B. Bolen With a tarnished reputation and a lack of sustainable innovation this article argues that, maybe, it is time for the pharmaceutical industry to… Read More

#Archive

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Business #Cellular assays #Chemistry #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Drug repositioning #Drug targets #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #Medicinal chemistry #Organic chemistry #Patent Law #RNA #Screening #Target validation #Toxicology

Overcoming the Limitations of Chemical Structure

Overcoming the Limitations of Chemical Structure By Dr Andy Vinter, Dr Steve Gardner and Dr Sally Rose The pharmaceutical business has been profoundly hampered by a ubiquitous and unexpected obstacles; the way it draws its chemical compounds. Scientists, patent agents and business decision makers from R&D, safety, and in-licensing are… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Animal models #Automation / robotics #Biomarkers #Business #Chemical engineering #Chemistry #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Genetics / genomes #Genomics #High throughput screening #Lead discovery #Molecular medicine #Oncology #PCR #Protein chemistry / Proteomics #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Therapeutics

The Benefits of Biological Modelling

The Benefits of Biological Modelling By Gordon Webster The enormous challenge posed by the complexity of biological systems represents a potential intellectual impasse to researchers and threatens to stall future progress in basic biology and healthcare. In recent years, increasing reliance on correlative approaches to biology has failed to resolve… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Biochemistry #Biomarkers #Business #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene editing #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #Immunology #Lead discovery #Microbiology #Molecular medicine #Oncology #PCR #Pharmacogenomics #Precision medicine #Protein chemistry / Proteomics #Regulatory #RNA #Sequencing #Stem cells #System biology #Systems biology #Target validation #Translational #Translational chemistry

Generation II DNA Sequencing Technologies

Generation II DNA Sequencing Technologies By Dr Stephen F. Kingsmore, Dr Jenny C. van Velkinburgh, Dr Joann Mudge, and Dr Gregory D. May Generation II DNA sequencing has been widely heralded as a disruptive technology, generating tens of millions of random short sequences at efficiencies up to 20,000-fold greater than… Read More

#Archive